MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced a significant capacity expansion of its Kangaroo™ ePump and Kangaroo™ Joey enteral feeding pumps and sets. This announcement comes in the wake of a recent announcement of a competitor’s exit from the enteral feeding pump market in the United States.
“With this investment, we are confident that we can provide ample supply to meet market needs today and in the future. All Kangaroo feeding pumps and sets are currently in stock and available for shipment.”
“Covidien has increased its inventory of enteral feeding pumps and its feeding set capacity to ensure that there is no shortage in the market,” said Gabriel McHugh, Franchise Director of Marketing at Covidien. “With this investment, we are confident that we can provide ample supply to meet market needs today and in the future. All Kangaroo feeding pumps and sets are currently in stock and available for shipment.”
For 30 years, clinicians have relied on Kangaroo enteral feeding pumps to feed and hydrate their patients. Covidien offers Kangaroo feeding pump technology in both institutional and ambulatory options.
- The Kangaroo ePump enteral feeding pump is optimized for the institutional setting with fully programmable variable feed, flush and hydration capabilities and easy to use ATM-style programming. It is accompanied by a full portfolio of feeding sets featuring safe enteral connections.
- The Kangaroo Joey enteral feeding pump feature set matches the Kangaroo ePump but with fully ambulatory capabilities, lightweight design and an extended battery life of 18 hours, it is ideal for the home setting.
All Kangaroo enteral feeding products feature safe enteral connections including:
- Stepped connectors that have been designed with a larger tip to prevent accidental connection to IV tubes while providing a secure connection with Kangaroo feeding tubes
- Purple color-coding to identify a nutritional port not for IV access.
“In addition to supplying a market-leading product, Covidien prides itself on providing comprehensive product training and support,” Mr. McHugh added. “Our sales and clinically trained in-service teams are prepared to support customer requirements. Additionally, we provide 24/7 in-service training at www.kangaroopumptraining.com.”
For additional information regarding Covidien’s pumps, service or supply capabilities, customers may contact their local Covidien representative or visit www.covidien.com/kangaroo.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.